BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 15268709)

  • 1. Expression profiles of p63, p53, survivin, and hTERT in skin tumors.
    Park HR; Min SK; Cho HD; Kim KH; Shin HS; Park YE
    J Cutan Pathol; 2004 Sep; 31(8):544-9. PubMed ID: 15268709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin.
    Sakiz D; Turkmenoglu TT; Kabukcuoglu F
    Pathol Res Pract; 2009; 205(9):589-94. PubMed ID: 19577853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.
    Kim KH; Park EJ; Seo YJ; Cho HS; Kim CW; Kim KJ; Park HR
    J Dermatol; 2006 May; 33(5):319-25. PubMed ID: 16700663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
    Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
    Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of p63 in actinic keratoses, seborrheic keratosis, and cutaneous squamous cell carcinomas.
    Wrone DA; Yoo S; Chipps LK; Moy RL
    Dermatol Surg; 2004 Oct; 30(10):1299-302. PubMed ID: 15458526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
    Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S
    Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors.
    Matsumoto M; Furihata M; Kurabayashi A; Ohtsuki Y
    Oncol Rep; 2004 Nov; 12(5):1039-43. PubMed ID: 15492790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma.
    Lo Muzio L; Santarelli A; Caltabiano R; Rubini C; Pieramici T; Trevisiol L; Carinci F; Leonardi R; De Lillo A; Lanzafame S; Bufo P; Piattelli A
    Hum Pathol; 2005 Feb; 36(2):187-94. PubMed ID: 15754296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p63 expression in normal skin and usual cutaneous carcinomas.
    Reis-Filho JS; Torio B; Albergaria A; Schmitt FC
    J Cutan Pathol; 2002 Oct; 29(9):517-23. PubMed ID: 12358808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.
    Saglam O; Salama M; Meier F; Chaffins M; Ma C; Ormsby A; Lee M
    Am J Dermatopathol; 2008 Apr; 30(2):123-6. PubMed ID: 18360114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.
    Khan Z; Tiwari RP; Mulherkar R; Sah NK; Prasad GB; Shrivastava BR; Bisen PS
    Head Neck; 2009 Aug; 31(8):1039-48. PubMed ID: 19340865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of ezrin in epithelial skin tumors: cytoplasmic ezrin immunoreactivity in squamous cell carcinoma.
    Park HR; Min SK; Min K; Jun SY; Seo J; Kim KH; Choi J
    Int J Dermatol; 2010 Jan; 49(1):48-52. PubMed ID: 20465611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
    Puizina-Ivić N; Sapunar D; Marasović D; Mirić L
    Coll Antropol; 2008 Oct; 32 Suppl 2():61-5. PubMed ID: 19138009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p63 immunostaining in destained bronchoscopic cytological specimens.
    Shtilbans V; Szporn AH; Wu M; Burstein DE
    Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
    Pelosi G; Pasini F; Olsen Stenholm C; Pastorino U; Maisonneuve P; Sonzogni A; Maffini F; Pruneri G; Fraggetta F; Cavallon A; Roz E; Iannucci A; Bresaola E; Viale G
    J Pathol; 2002 Sep; 198(1):100-9. PubMed ID: 12210069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of p63 and survivin in cholesteatomas.
    Park HR; Min SK; Min K; Jun SY; Seo J; Kim HJ
    Acta Otolaryngol; 2009 Mar; 129(3):268-72. PubMed ID: 18615329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression in Bowen's disease and in microinvasive squamous cell carcinoma of the skin.
    Hughes JH; Robinson RA
    Mod Pathol; 1995 Jun; 8(5):526-9. PubMed ID: 7675772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression.
    Allen SM; Florell SR; Hanks AN; Alexander A; Diedrich MJ; Altieri DC; Grossman D
    Cancer Res; 2003 Feb; 63(3):567-72. PubMed ID: 12566297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.
    Burnworth B; Arendt S; Muffler S; Steinkraus V; Bröcker EB; Birek C; Hartschuh W; Jauch A; Boukamp P
    Eur J Cell Biol; 2007 Dec; 86(11-12):763-80. PubMed ID: 17198740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation.
    Pizem J; Cör A; Gale N
    Histopathology; 2004 Aug; 45(2):180-6. PubMed ID: 15279637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.